预约演示
更新于：2026-01-28
Gadobutrol
钆布醇
更新于：2026-01-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1998-12-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H31GdN4O9 |
InChIKeyZPDFIIGFYAHNSK-ZCTZICQLSA-K |
CAS号770691-21-9 |
关联
94
项与 钆布醇 相关的临床试验NCT07275814
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
NCT07275723
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)
NCT06854458
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study
100 项与 钆布醇 相关的临床结果
登录后查看更多信息
100 项与 钆布醇 相关的转化医学
登录后查看更多信息
100 项与 钆布醇 相关的专利（医药）
登录后查看更多信息
697
项与 钆布醇 相关的文献（医药）2025-12-01MAGNETIC RESONANCE IN MEDICINE
Dynamic contrast enhanced‐magnetic resonance fingerprinting (DCE ‐MRF ): A new quantitative MRI method to reliably assess tumor vascular perfusion
Article
作者: Wu, Chunying ; Schiemann, Barbara J. ; Yu, Xin ; Griswold, Mark A. ; Dupuis, Andrew ; Zhu, Yuran ; MacAskill, Christina J. ; Schiemann, William P. ; Wang, Guanhua ; Kavran, Michael ; Erokwu, Bernadette O. ; Pagel, Mark D. ; Flask, Chris A. ; Dhakan, Chetan B.
Abstract:
Purpose:
The clinical utility of conventional DCE‐MRI methods is limited by the use of conventional qualitative dynamic T1‐weighted images, resulting in poor reproducibility. This study presents the initial implementation of a new DCE‐magnetic resonance fingerprinting (DCE‐MRF) methodology to provide reproducible, quantitative assessments of tumor vascular perfusion.
Methods:
The DCE‐MRF acquisition combines multiple T1 preparations, highly undersampled spiral trajectories (R = 48), a low‐rank reconstruction method, and low tip angles on a 9.4 T preclinical MRI scanner to rapidly generate dynamic T1 maps (23‐s temporal resolution). In vitro validation experiments were conducted across a range of Gadovist concentrations to assess accuracy and temporal precision in comparison to conventional methods. The DCE‐MRF method was also evaluated in vivo in an orthotopic 4T1 mouse model of breast cancer (n = 25). Pharmacokinetic modeling of the in vivo data was performed using a linear reference region model (LRRM).
Results:
In vitro DCE‐MRF studies demonstrated good agreement with conventional MRI methods for T1 measurements (R2 0.99). The iterative low‐rank reconstruction method also reduced artifacts compared to conventional reconstruction methods. DCE‐MRF demonstrated a 2‐ to 3‐fold reduction in temporal variability compared to conventional DCE‐MRI, and enabled effective in vivo pharmacokinetic modeling using the LRRM by generating voxelwise maps of RKtrans and kep,T as measures of tumor vascular perfusion.
Conclusions:
DCE‐MRF represents a new inherently quantitative approach to measuring tumor vascular perfusion that can be used in animal models and eventually in patients.
2025-12-01MEDICAL PHYSICS
Efficient estimation of gadolinium‐based contrast agent concentration using transient‐state keyhole MR‐STAT
Article
作者: Fuderer, Miha ; Xu, Fei ; van der Kemp, Wybe J. M. ; Versteeg, Edwin ; van den Berg, Cornelis A. T. ; Sbrizzi, Alessandro ; Liu, Hongyan ; van den Heide, Oscar
Abstract:
Background:
Fast quantitative MRI (qMRI) techniques have emerged to quantify multiple tissue parameters from a single acquisition in clinically feasible scan times. To integrate fast qMRI techniques into a clinical MRI protocol, one needs to consider imaging after injection of a contrast agent (e.g., dynamic contrast‐enhanced [DCE] imaging). However, fully repeating the multi‐parametric scan after the injection requires lengthy scan times, which are impractical for tracking the contrast agent concentration.
Purpose:
This work aimed to develop and validate an accelerated multi‐parametric method capable of estimating the concentration of Gadolinium‐based contrast agents (GBCAs) in a more time‐efficient way.
Methods:
We designed an accelerated 2D Magnetic Resonance Spin TomogrAphy in Time‐domain (MR‐STAT) protocol and tested it on a 3T MRI scanner. This is achieved by combining transient‐state acquisitions with Cartesian keyhole‐based acceleration. Based on the reconstructed
T1
values, GBCA concentrations were quantified in phantoms containing water, manganese chloride, and five different concentrations of gadobutrol (Gadovist), ranging from 0.05 to 0.9 mM. Linear regression analysis between the estimated GBCA concentration and the reference values was performed to assess the accuracy. The GBCA concentration quantification method was then applied for synthetic patient data and a hybrid human/phantom study to demonstrate the feasibility of this method.
Results:
The accelerated MR‐STAT protocol, with an undersampling factor of 4, provided accurate
T1
,
T2,
and GBCA concentration measurements. Estimated GBCA concentrations were in a strong linear relationship with reference values, with a slope and intercept on simple linear regression analysis of 1.034 and 0.009, respectively.
Conclusion:
We present a multi‐parametric approach for quantitatively assessing the concentration of gadolinium in vitro and in a hybrid in vivo/in vitro controlled setup using the accelerated MR‐STAT protocol. The concentration of gadobutrol in the range of 0.05–0.9 mM could be measured in a clinically applicable scan time using the proposed method, but needs further in vivo validation.
2025-12-01Alzheimers & Dementia
A 24 hour neuroimaging protocol to track solute transport from blood to the CSF as a surrogate for protein clearance
Article
作者: Meyer, Briana R ; Levendovszky, Swati Rane ; Iliff, Jeffrey J
Abstract:
Background:
Neurofluids play a key role in clearing amyloid and tau proteins from the brain. MRI studies using intrathecal gadolinium‐based contrast agents (GBCA) show transport from the cerebrospinal fluid (CSF) into brain tissue. Additionally, studies using intravenous (IV) GBCA demonstrate blood‐to‐CSF transfer, though these studies often include limited time points, when vascular GBCA concentration is high, making it hard to parse parenchymal or CSF concentration. We performed hourly MRI scans over 24 hours after IV GBCA to detect CSF contrast transport, aiming to track protein movement through the brain.
Method:
Seven healthy adults (ages 23‐57, 2 female) underwent 24 MRI scans, starting with a baseline, followed by scans at 20 minutes and then hourly from 1 to 22 hours post‐IV GBCA (Gadobutrol, 0.1 mmol/kg). Imaging included 3D‐QALAS for T1/T2 mapping, a heavy T2‐weighted FLAIR sequence, and a 3D Black Blood sequence. T1‐w images from the QALAS provided tissue masks for gray matter (GM), white matter (WM), subarachnoid space (SAS), and the lateral ventricles (LV). Manual regions included the sagittal sinus (SS), optic nerve (O), trigeminal nerve (T), choroid plexus (CP), and arachnoid cuff exit (ACE) points. Signal intensity changes were noted for all time points in all regions. GBCA concentration was calculated using T1 mapping data.
Result:
In the CSF, GBCA concentration was 0.007 mM in the SAS and 0.0007 mM the LV at 20 mins, and then quickly settled to 0.002 and 0.001 mM until 22 hours. The SAS had a higher GBCA concentration than LV, suggesting a direct blood‐to‐CSF exchange near the SAS. This could be explained by contrast leakage around ACE points, visible on T2w FLAIR images. Additionally, the Black Blood sequence showed sustained GBCA in the parasagittal dura. GBCA was retained the longest in the optic nerve (∼19 hours), while it dissipated fastest around ACE points. No enhancement was observed in the parenchyma. In the CP, the concentration was 0.02 mM at 20 mins but was negligible by 4 hours.
Conclusion:
IV‐GBCA can track contrast transport from the vascular to the CSF compartment. GBCA transfers to the ventricles and SAS through multiple mechanisms, with varying transport rates across different nerves.
100 项与 钆布醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 美国 | 2019-07-12 | |
| 主动脉疾病 | 美国 | 2016-04-27 | |
| 乳腺疾病 | 美国 | 2014-12-29 | |
| 中枢神经系统血管畸形 | 美国 | 2011-03-14 | |
| 脑血管疾病 | 美国 | 2011-03-14 | |
| 造影剂 | 澳大利亚 | 1998-12-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉狭窄 | 临床3期 | 美国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 中国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 阿根廷 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 澳大利亚 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 奥地利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 捷克 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 法国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 德国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 意大利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 波兰 | 2011-05-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 141 | Reduced Dose Gadobutrol | 鹽醖選製醖獵獵糧淵簾(壓窪構選醖願窪積廠壓) = 築蓋築觸範壓鹽淵憲鑰 衊選淵範獵簾夢遞艱鬱 (繭製獵鏇壓獵選淵範鑰 ) 更多 | 积极 | 2021-06-16 | |
Standard Dose Gadoterate | 鹽醖選製醖獵獵糧淵簾(壓窪構選醖願窪積廠壓) = 淵鹹繭簾網壓製網願壓 衊選淵範獵簾夢遞艱鬱 (繭製獵鏇壓獵選淵範鑰 ) 更多 | ||||||
临床4期 | - | 157 | Gadoterate (Gadoterate 0.1 mmol/kg BW) | 獵網襯夢獵廠淵遞選衊(憲蓋鹽齋襯遞窪醖簾廠) = 齋願顧餘壓壓網醖窪蓋 衊廠鏇鏇選憲願簾選選 (蓋衊廠蓋膚鑰膚獵窪觸, 0.252) 更多 | - | 2021-04-28 | |
(Gadobutrol 0.075 mmol/kg BW) | 獵網襯夢獵廠淵遞選衊(憲蓋鹽齋襯遞窪醖簾廠) = 遞繭襯膚鹽淵獵糧糧願 衊廠鏇鏇選憲願簾選選 (蓋衊廠蓋膚鑰膚獵窪觸, 0.201) 更多 | ||||||
临床3期 | 19 | PET/MR scanner+C-11 choline PET tracer+Gadobutrol | 範齋網鏇範繭齋齋壓襯(網齋鏇襯夢鹹糧窪夢築) = 鹽觸簾製顧積憲夢夢顧 艱餘廠餘構觸網糧餘襯 (襯艱膚鬱鏇範築襯簾鑰, 1.8) 更多 | - | 2021-02-08 | ||
临床3期 | 426 | 範壓網膚齋壓鬱醖積選 = 簾艱鹹簾夢窪壓構選網 範築壓構膚遞鬱壓願觸 (製鬱繭繭構鹽遞構鹹願, 築築鑰繭餘繭淵製鬱鏇 ~ 鏇鹽選選蓋築淵憲衊網) 更多 | - | 2018-05-16 | |||
临床3期 | 478 | 獵齋遞觸壓繭壓醖艱淵 = 積鹽網淵鹽憲蓋觸窪糧 製糧顧壓顧築繭衊廠顧 (艱艱願鹽繭餘憲衊醖願, 醖憲觸壓艱憲艱憲構糧 ~ 鏇鹽觸糧觸窪窪廠鹹構) 更多 | - | 2018-05-16 | |||
N/A | 23,708 | 構構顧範鬱廠構繭艱淵(製獵築醖觸淵簾夢醖積) = 鹽遞選遞獵網遞餘鑰窪 遞夢願鬱齋齋淵鑰蓋鏇 (積製觸遞網壓鹽鑰衊製 ) 更多 | 积极 | 2017-01-01 | |||
临床4期 | 279 | (Gadovist® (Reader 1)) | 鏇窪鹹願廠蓋憲遞鏇齋 = 遞築鹽餘遞鬱壓鏇範襯 顧鹹範鑰鬱餘繭顧齋觸 (糧蓋膚艱鏇淵獵願廠夢, 襯鬱廠襯鏇窪構衊製鏇 ~ 觸艱選繭選艱簾糧繭鹽) | - | 2016-10-25 | ||
(Dotarem® (Reader 1)) | 鏇窪鹹願廠蓋憲遞鏇齋 = 鹽積淵鹽鬱觸窪淵遞醖 顧鹹範鑰鬱餘繭顧齋觸 (糧蓋膚艱鏇淵獵願廠夢, 網廠餘鑰遞衊簾築夢衊 ~ 積簾壓衊憲網憲憲繭顧) | ||||||
临床3期 | 906 | 鹹淵淵構積鹹壓襯夢襯(積餘鹹艱願蓋餘夢夢獵) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. 選顧觸網製願積選網選 (鑰糧觸鹽齋範鏇鏇積遞 ) | 积极 | 2016-07-01 | |||
临床3期 | 292 | 獵網餘鑰網鹹淵鏇淵糧(製積壓窪繭網鹽築構製) = 憲襯網壓構餘醖醖鹹膚 願憲選鑰製憲廠餘積鬱 (蓋鹽積遞廠鹹製淵願簾 ) 更多 | 积极 | 2016-04-29 | |||
临床2期 | 232 | (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)) | 壓齋鬱衊衊壓憲醖蓋壓 = 鑰鹹積餘觸憲蓋廠齋膚 襯壓蓋鏇醖廠願鏇鹹製 (積蓋遞築簾觸齋繭遞鹹, 夢鏇繭艱鹽製積簾獵構 ~ 鹽鬱構鹹簾艱遞餘膚窪) 更多 | - | 2012-06-28 | ||
(Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)) | 壓齋鬱衊衊壓憲醖蓋壓 = 艱鏇鏇壓鏇膚觸繭鬱築 襯壓蓋鏇醖廠願鏇鹹製 (積蓋遞築簾觸齋繭遞鹹, 獵餘網簾製艱夢積願衊 ~ 窪繭憲鹽壓窪製願繭鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用